Assessing JBT Marel (JBTM) Valuation After Its 2025 Name Change And Recent Share Price Momentum

JBT Marel (JBTM) entered 2025 with a formal name change from John Bean Technologies Corporation, a shift that places its food processing and automation focus front and center for investors tracking the stock. See our latest analysis for JBT Marel. The name change comes as JBT Marel’s share price trades at $156.29, with a 90 day share price return of 14.29% and a 1 year total shareholder return of 28.51%, suggesting building momentum rather than short term noise. If you are looking for other food and industrial automation names, it can also help to widen your net with fast growing stocks with high insider ownership. With the shares up strongly over 1 year, trading near a US$160 analyst target and screening with a low value score, the key question is whether JBT Marel still offers upside or if the market is already pricing in future growth. Most Popular Narrative: 2.5% Undervalued The most followed narrative puts JBT Marel’s fair value at US$160.25, slightly above the last close at US$156.29, framing a modest upside case. The analysts have a consensus price target of $149.417 for JBT Marel based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $177.5, and the most bearish reporting a price target of just $85.0. Read the complete narrative. Curious what justifies a higher fair value than that consensus target? The narrative focuses on expectations of faster revenue expansion, margin repair and a richer future earnings multiple. Want to see how those pieces fit together? Result: Fair Value of $160.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh tariff pressures and ongoing merger integration work. Either of these factors could squeeze margins and challenge the current upside case. Find out about the key risks to this JBT Marel narrative. Another View: Multiples Paint A Tighter Picture That 2.5% undervalued fair value narrative sits next to a more cautious read when you look at simple sales multiples. JBT Marel trades on a P/S of 2.5x, which is the same as its fair ratio of 2.5x, slightly above the US Machinery industry at 2.1x, yet below peers at 3.3x. In plain terms, the market is already paying a full price relative to the sector, while still leaving some room versus peers. The margin for error on future assumptions looks slim rather than wide, which begs the question: how comfortable are you with that balance of risk and potential reward? See what the numbers say about this price — find out in our valuation breakdown. NYSE:JBTM P/S Ratio as at Jan 2026 Build Your Own JBT Marel Narrative If you see the numbers differently or prefer to piece together your own view, you can build a personalized JBT Marel story in just a few minutes, starting with Do it your way. A great starting point for your JBT Marel research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If you are serious about broadening your watchlist, do not stop at one stock. Use targeted screeners to surface ideas you might otherwise miss. Spot potential value opportunities before they hit the headlines by scanning these 884 undervalued stocks based on cash flows tied to stronger cash flow profiles. Ride the growth of machine learning and automation by focusing on these 25 AI penny stocks shaping real world use cases and commercial adoption. Tap into the growing intersection of healthcare and algorithms through these 30 healthcare AI stocks, where data driven medicine is becoming more central to treatment decisions. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.